AZTherapies Overview
- Founded
-
2011

- Status
-
Private
- Employees
-
16

- Latest Deal Type
-
2ndary - Private
- Investors
-
17
AZTherapies General Information
Description
Operator of a biopharmaceutical company intended to offer treatment for multiple neurodegenerations and neuroinflammation-related CNS diseases. The company offers a novel multi-action combination drug regimen that is used to modify disease progression by slowing down or halting Alzheimer's disease early in its development, enabling healthcare providers to easily cure Alzheimer's patients without any surgery.
Contact Information
Website
www.aztherapies.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 200 Clarendon Street
- 17th Floor
- Boston, MA 02116
- United States
+1 (617) 000-0000
AZTherapies Timeline
AZTherapies Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
8. Secondary Transaction - Private | 01-Sep-2021 | 00000 | Completed | Clinical Trials - Phase 3 | ||
7. Later Stage VC (Series C1) | 29-Sep-2020 | 000.00 | 00000 | 00000 | Completed | Clinical Trials - Phase 3 |
6. Debt - PPP | 19-May-2020 | 000.00 | Completed | Clinical Trials - Phase 3 | ||
5. Later Stage VC (Series C) | 31-Jan-2020 | 000.00 | 000.00 | 00000 | Completed | Clinical Trials - Phase 3 |
4. Later Stage VC (Series B) | 16-Oct-2018 | 000.00 | 000.00 | 00000 | Completed | Clinical Trials - Phase 3 |
3. Later Stage VC (Series A) | 0000 | 000.00 | 00000 | Completed | Clinical Trials - Phase 3 | |
2. Later Stage VC (Series A) | 06-Feb-2017 | $16.4M | $26.4M | 00000 | Completed | Clinical Trials - Phase 3 |
1. Early Stage VC | 06-Jan-2015 | $10M | $10M | Completed | Clinical Trials - Phase 3 |
AZTherapies Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series C1 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
Series C | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
Series B | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
Series A-2 | 0,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 00.0 | 0.000 | |
Series A-1 | 2,084,052 | $0.000100 | $3.33 | $3.33 | 1x | $3.33 | 3.8% | |
Series A | 4,212,559 | $0.000100 | $4 | $4 | 1x | $4 | 7.69% |
AZTherapies Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Operator of a biopharmaceutical company intended to offer treatment for multiple neurodegenerations and neuroinflammatio
Drug Discovery
Boston, MA
16
As of 2023
00000
00000000000
00000
AZTherapies Competitors (48)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Alzheon | Venture Capital-Backed | Framingham, MA | 00 | 000.00 | 00000000000 | 000.00 |
0000000 | Venture Capital-Backed | San Carlos, CA | 00 | 000.00 | 00000000000 | 000.00 |
000 000000000000 | Venture Capital-Backed | Durham, NC | 00 | 000.00 | 00000000000 | 000.00 |
000000000000 | Venture Capital-Backed | Clarksville, MD | 0 | 00.000 | 00000000000 | |
00000 000000000000 | Formerly VC-backed | Grand Rapids, MI | 0 | 0000 | 000000&0 | 0000 |
AZTherapies Patents
AZTherapies Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2019242381-A1 | Car-treg-based therapies for treating neurodegenerative diseases | Pending | 27-Mar-2018 | 000000000 | |
CA-3095298-A1 | Car-treg-based therapies for treating neurodegenerative diseases | Pending | 27-Mar-2018 | 000000000 | |
EP-3773629-A1 | Car-treg-based therapies for treating neurodegenerative diseases | Pending | 27-Mar-2018 | 000000000 | |
EP-3773629-A4 | Car-treg-based therapies for treating neurodegenerative diseases | Pending | 27-Mar-2018 | 000000000 | 0 |
US-20210023137-A1 | Car-treg-based therapies for treating neurodegenerative diseases | Pending | 27-Mar-2018 | A61K35/17 |
AZTherapies Executive Team (9)
AZTherapies Board Members (13)
Name | Representing | Role | Since |
---|---|---|---|
David Elmaleh Ph.D | AZTherapies | Scientific Founder, Executive Chairman & Chief Scientific Officer | 000 0000 |
David King | Self | Board Member & Business Advisor | 000 0000 |
David Taft | Self | Board Member | 000 0000 |
George Behrakis | AZTherapies | Board Member | 000 0000 |
Gillian Sandler | Self | Board Member | 000 0000 |
AZTherapies Signals
AZTherapies Investors (17)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Black Granite Capital | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
Catalytic Impact Foundation | Not-For-Profit Venture Capital | Minority | 000 0000 | 000000 0 | |
DEFTA Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Duopharma Biotech | PE-Backed Company | Minority | 000 0000 | 000000 0 | |
Wooshin Venture Investment | Venture Capital | Minority | 000 0000 | 000000 0 |
AZTherapies Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000 0000000 | 24-Oct-2019 | 0000000000 | Biotechnology | 00000 000 |